Oral antihyperglycemic therapy for type 2 diabetes mellitus.
about
Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivityGedunin and Azadiradione: Human Pancreatic Alpha-Amylase Inhibiting Limonoids from Neem (Azadirachta indica) as Anti-Diabetic AgentsUltrafiltration liquid chromatography combined with high-speed countercurrent chromatography for screening and isolating potential α-glucosidase and xanthine oxidase inhibitors from Cortex Phellodendri.Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information SystemLong-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.Potent α-amylase inhibitory activity of Indian Ayurvedic medicinal plants.Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.Standardized extract of Ficus deltoidea stimulates insulin secretion and blocks hepatic glucose production by regulating the expression of glucose-metabolic genes in streptozitocin-induced diabetic rats.Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.Anti-Hyperglycemic Properties of Crude Extract and Triterpenes from Poria cocos.The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsLinagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.Screening and determination for potential α-glucosidase inhibitory constituents from Dalbergia odorifera T. Chen using ultrafiltration-LC/ESI-MS(n).Synthetic (+)-antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activitiesComparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study.Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.Antioxidation and antiglycation of Fagopyrum tataricum ethanol extract.New onset diabetes after transplantation (NODAT): an overview.Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosisCharacterization of different crystal forms of the alpha-glucosidase MalA from Sulfolobus solfataricusCardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetesBiotransformation of Momordica charantia fresh juice by Lactobacillus plantarum BET003 and its putative anti-diabetic potential.Silk fibroin hydrolysate exerts an anti-diabetic effect by increasing pancreatic β cell mass in C57BL/KsJ-db/db mice.Octreotide's role in the management of sulfonylurea-induced hypoglycemia.Antidiabetic effects of pterosin A, a small-molecular-weight natural product, on diabetic mouse modelsSasa borealis extract exerts an antidiabetic effect via activation of the AMP-activated protein kinase.Tagatose, a new antidiabetic and obesity control drug.Pharmacogenetics of glucose-lowering drug treatment: a systematic review.Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing.Hypoglycemic Effect of Padina arborescens Extract in Streptozotocin-induced Diabetic Mice.Repaglinide, but not nateglinide administered supraspinally and spinally exerts an anti-diabetic action in d-glucose fed and streptozotocin-treated mouse modelsMetformin based dual-combination therapies in drug naïve type 2 diabetic patients.Drug-induced hypoglycaemia: an update.Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome.Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes.The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation.Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.Antioxidant and α -amylase inhibitory property of phyllanthus virgatus L.: an in vitro and molecular interaction study
P2860
Q28542711-381221B4-BDB8-4907-8153-912A64F37432Q28550293-EF7F212E-25D6-42FB-907E-87A6140DA81DQ30833906-712BEE1C-E93F-4B18-89CF-72948D17D255Q33288486-F0E2E6F7-6F82-4E31-8AD5-F60F514BBF8DQ33585566-186DAA4E-7614-48B4-86F6-022EA9E933B5Q33798708-AAD46ADC-2B6E-4A97-AE3B-519099A12A33Q33882138-B56F2840-1EA8-471A-9929-CA2984BA9E8FQ33889659-B70B0012-EFEF-4DDC-A0E9-4F17FDFE5BBFQ34044817-2885C1B1-8E7D-4EC7-9FFC-02228EAD3782Q34161200-4E02C19F-6FDC-4D2C-A082-E8D6A52ED312Q34173158-BD81BD1E-BF65-49FC-BE59-3AC6BFD55FA8Q34524510-1EEFE706-DB43-4260-87D1-1F0CE2C87AD9Q34637776-CAF49F25-334E-44F0-9B6C-E2E29CF85353Q34787436-D6A238D0-7B55-4016-A9D4-BEEAB3A4E38DQ34795679-1236DFEB-9D1F-4381-8179-2570FDE3BF37Q34828916-933DD719-392B-461A-9A8A-D4B4765E75A7Q35038326-5AF4CC41-3DAB-410C-B651-1240FE4CECCAQ35074817-D92F4878-B487-467F-B6A2-25CEAF735FC8Q35092351-C02687B7-B215-4C5A-A4C2-DECD6F7D16ACQ35561066-B422D2AE-3856-4AE1-8B17-92B9B5AC49DEQ35994962-D60D8F12-E791-4C82-B04F-61370E526006Q36088468-042523FD-C825-4339-A044-A5A0FBE78B38Q36244358-8BF77FD3-7C64-4204-84FE-19A4D759A0CBQ36514951-C4B8E389-376B-4A44-8FBD-2C223FC83E81Q36549055-095799CB-C4EF-4ED9-8530-A712E0E07489Q36560620-DB0FFAEA-D2B7-40FB-AD5D-713E66B12BE9Q36609158-F0080802-A9A1-4B52-B276-405586DB495AQ36973806-CA957D62-EDDD-4FCC-AEC0-EC2C17906CC2Q36982648-9E3249B5-0BF0-4151-B280-35959987F414Q37079820-AEC3A31C-3CE7-4189-B8A2-A8523F07DBFCQ37182800-E724F10C-5404-48DE-A878-3D41E0732161Q37400463-A6566F8A-6315-4C4D-895D-A46D2E3DF92AQ37417621-ED891AD4-3C46-485A-9BAC-17A519F1E227Q37435700-2C5C41D4-2661-4711-863B-10E48155E0C5Q37799813-6910D157-CE20-4FE9-855E-9128A21F4F67Q37900938-D9919767-0232-4F19-A8F8-E294777F11F1Q38128788-64F1B7D3-8689-4448-A2FA-8B10C0B3F479Q38451453-0918B6E0-4D87-4843-9909-9092099FE457Q38582254-B4782E40-E4AE-45EF-86CE-3BF20F166476Q39365151-9C2FB2B8-A325-4002-B500-48B86AC7EB9D
P2860
Oral antihyperglycemic therapy for type 2 diabetes mellitus.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Oral antihyperglycemic therapy for type 2 diabetes mellitus.
@ast
Oral antihyperglycemic therapy for type 2 diabetes mellitus.
@en
type
label
Oral antihyperglycemic therapy for type 2 diabetes mellitus.
@ast
Oral antihyperglycemic therapy for type 2 diabetes mellitus.
@en
prefLabel
Oral antihyperglycemic therapy for type 2 diabetes mellitus.
@ast
Oral antihyperglycemic therapy for type 2 diabetes mellitus.
@en
P2860
P356
P1476
Oral antihyperglycemic therapy for type 2 diabetes mellitus
@en
P2093
I George Fantus
P2860
P304
P356
10.1503/CMAJ.1031414
P407
P577
2005-01-01T00:00:00Z